Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.

Article Snippet: Notably, we first found that HDL-C levels were positively associated with plasma p-tau217 measured by Lumipulse, even after adjusting for amyloid pathology.

Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Kaplan–Meier curves showing risk of conversion to AD dementia based on plasma p-tau217 biomarkers Participants were stratified into high (above cutoff) and low (below cutoff) groups using cutoff values determined by the maximum Youden index. ( A ) Simoa p-tau217, ( B ) Lumipulse p-tau217, and ( C ) Lumipulse p-tau217/Aβ42 ratio. Participants in the high-biomarker group exhibited significantly higher rates of conversion to AD dementia during follow-up. Log-rank test p-values were as follows: Simoa p-tau217 (p = 0.002), Lumipulse p-tau217 (p < 0.001), and Lumipulse p-tau217/Aβ42 (p < 0.001). Numbers at risk are shown in the bottom.

Article Snippet: Notably, we first found that HDL-C levels were positively associated with plasma p-tau217 measured by Lumipulse, even after adjusting for amyloid pathology.

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.

Article Snippet: We evaluated the predictive performance of plasma biomarkers measured using Lumipulse—including p-tau217, Aβ42/Aβ40 ratio, GFAP, and p-tau217/Aβ42 ratio for identifying amyloid pathology (Supplementary Fig. 3).

Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Kaplan–Meier curves showing risk of conversion to AD dementia based on plasma p-tau217 biomarkers Participants were stratified into high (above cutoff) and low (below cutoff) groups using cutoff values determined by the maximum Youden index. ( A ) Simoa p-tau217, ( B ) Lumipulse p-tau217, and ( C ) Lumipulse p-tau217/Aβ42 ratio. Participants in the high-biomarker group exhibited significantly higher rates of conversion to AD dementia during follow-up. Log-rank test p-values were as follows: Simoa p-tau217 (p = 0.002), Lumipulse p-tau217 (p < 0.001), and Lumipulse p-tau217/Aβ42 (p < 0.001). Numbers at risk are shown in the bottom.

Article Snippet: We evaluated the predictive performance of plasma biomarkers measured using Lumipulse—including p-tau217, Aβ42/Aβ40 ratio, GFAP, and p-tau217/Aβ42 ratio for identifying amyloid pathology (Supplementary Fig. 3).

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.

Article Snippet: • Plasma p-tau217 values showed a correlation between LUMIPULSE and Simoa platforms.

Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Kaplan–Meier curves showing risk of conversion to AD dementia based on plasma p-tau217 biomarkers Participants were stratified into high (above cutoff) and low (below cutoff) groups using cutoff values determined by the maximum Youden index. ( A ) Simoa p-tau217, ( B ) Lumipulse p-tau217, and ( C ) Lumipulse p-tau217/Aβ42 ratio. Participants in the high-biomarker group exhibited significantly higher rates of conversion to AD dementia during follow-up. Log-rank test p-values were as follows: Simoa p-tau217 (p = 0.002), Lumipulse p-tau217 (p < 0.001), and Lumipulse p-tau217/Aβ42 (p < 0.001). Numbers at risk are shown in the bottom.

Article Snippet: • Plasma p-tau217 values showed a correlation between LUMIPULSE and Simoa platforms.

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.

Article Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 103 plots are shown.

Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Kaplan–Meier curves showing risk of conversion to AD dementia based on plasma p-tau217 biomarkers Participants were stratified into high (above cutoff) and low (below cutoff) groups using cutoff values determined by the maximum Youden index. ( A ) Simoa p-tau217, ( B ) Lumipulse p-tau217, and ( C ) Lumipulse p-tau217/Aβ42 ratio. Participants in the high-biomarker group exhibited significantly higher rates of conversion to AD dementia during follow-up. Log-rank test p-values were as follows: Simoa p-tau217 (p = 0.002), Lumipulse p-tau217 (p < 0.001), and Lumipulse p-tau217/Aβ42 (p < 0.001). Numbers at risk are shown in the bottom.

Article Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 103 plots are shown.

Techniques: Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Diagnostic performance and cutoff points of plasma p-tau217 biomarkers for detecting amyloid pathology ( A ) ROC curves showing the AUCs of each plasma biomarker in discriminating amyloid pathology, as defined by the CSF Aβ42/Aβ40 ratio. ( B ) Simoa p-tau217, ( C ) Lumipulse p-tau217, and ( D ) Lumipulse p-tau217/Aβ42 × 10³ plots are shown. The red solid lines indicate the single-point cutoffs determined by the maximum Youden index. The red dashed lines represent the two-point cutoffs achieving >95% sensitivity and >95% specificity, with the intermediate zones shaded in red. For Lumipulse p-tau217, only one cutoff is shown as it meets both criteria using a single threshold. For Lumipulse p-tau217/Aβ42, the single-point and two-point cutoffs were identical, and thus only the red solid line is displayed. FDA-approved two-point cutoffs are indicated by blue dashed lines, with the intermediate zones shaded in blue.

Article Snippet: Plasma p-tau217 was measured using both Lumipulse G pTau217 Plasma kit on the LUMIPULSE G1200 and Simoa ALZpath kit on HD-X platform (Quanterix, Billerica, MA, USA).

Techniques: Diagnostic Assay, Clinical Proteomics, Biomarker Discovery

Journal: The Journal of Prevention of Alzheimer's Disease

Article Title: Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer’s disease neuroimaging initiative cohort

doi: 10.1016/j.tjpad.2026.100502

Figure Lengend Snippet: Kaplan–Meier curves showing risk of conversion to AD dementia based on plasma p-tau217 biomarkers Participants were stratified into high (above cutoff) and low (below cutoff) groups using cutoff values determined by the maximum Youden index. ( A ) Simoa p-tau217, ( B ) Lumipulse p-tau217, and ( C ) Lumipulse p-tau217/Aβ42 ratio. Participants in the high-biomarker group exhibited significantly higher rates of conversion to AD dementia during follow-up. Log-rank test p-values were as follows: Simoa p-tau217 (p = 0.002), Lumipulse p-tau217 (p < 0.001), and Lumipulse p-tau217/Aβ42 (p < 0.001). Numbers at risk are shown in the bottom.

Article Snippet: Plasma p-tau217 was measured using both Lumipulse G pTau217 Plasma kit on the LUMIPULSE G1200 and Simoa ALZpath kit on HD-X platform (Quanterix, Billerica, MA, USA).

Techniques: Clinical Proteomics, Biomarker Discovery